Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06756269 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06756269 · ClinicalTrials.gov record · last posted 2025-12-17

To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years

Name: To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years — clinical trial record (NCT06756269)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorShanghai Bovax Biotechnology Co., Ltd.

Started2025-01-15

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants.

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2024-12-31; most recent amendment 2025-12-16. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-12-16

Status change Active, Not Recruiting→Recruitingv2

2025-02-05

Status change Not Yet Recruiting→Active, Not Recruitingv1

Trial Details

NCT Number	NCT06756269
Lead Sponsor	Shanghai Bovax Biotechnology Co., Ltd.
Conditions	HPV Infection, HPV-Related Carcinoma, HPV-Related Intraepithelial Neoplasia, Genital Wart
Enrollment	330 participants
Start Date	2025-01-15
Primary Completion	2025-10-30 (estimated)
Study Completion	2026-01-13 (estimated)
Updated on ClinicalTrials.gov	2025-12-17